HVEM/TNFRSF14 Antibody (2742B) [Unconjugated]

MAB1050), followed by Allophycocyanin-conjugated Anti-Rabbit IgG Secondary Antibody (F0111) and Mouse Anti-Human PE-conjugated CD19 (FAB4867P). Cells were gated on Mouse Anti-Human Alexa Fluor® 405-conjugated CD14 (FAB3832V), Mouse Anti-Human Alexa Fluor® 488-conjugated CD3 (FAB100G), and Mouse Anti-Human Alexa Fluor® 700-conjugated CD56 (FAB24086N) negative populations. Staining was performed using our Staining Membrane-associated Proteins protocol. " > MAB1050), followed by Allophycocyanin-conjugated Anti-Rabbit IgG Secondary Antibody (F0111) and Mouse Anti-Human PE-conjugated CD19 (FAB4867P). Cells were gated on Mouse Anti-Human Alexa Fluor® 405-conjugated CD14 (FAB3832V), Mouse Anti-Human Alexa Fluor® 488-conjugated CD3 (FAB100G), and Mouse Anti-Human Alexa Fluor® 700-conjugated CD56 (FAB24086N) negative populations. Staining was performed using our Staining Membrane-associated Proteins protocol. " title="Human PBMC lymphocytes were stained with (A) Rabbit Anti-Human HVEM/TNFRSF14 Monoclonal Antibody (Catalog # MAB3563) or (B) isotype control antibody (MAB1050), followed by Allophycocyanin-conjugated Anti-Rabbit IgG Secondary Antibody (F0111) and Mouse Anti-Human PE-conjugated CD19 (FAB4867P). Cells were gated on Mouse Anti-Human Alexa Fluor® 405-conjugated CD14 (FAB3832V), Mouse Anti-Human Alexa Fluor® 488-conjugated CD3 (FAB100G), and Mouse Anti-Human Alexa Fluor® 700-conjugated CD56 (FAB24086N) negative populations. Staining was performed using our Staining Membrane-associated Proteins protocol. " />

Human PBMC lymphocytes were stained with (A) Rabbit Anti-Human HVEM/TNFRSF14 Monoclonal Antibody (Catalog # MAB3563) or (B) isotype control antibody (<a class=

MAB1050), followed by Allophycocyanin-conjugated Anti-Rabbit IgG Secondary Antibody (F0111) and Mouse Anti-Human Alexa Fluor® 488-conjugated CD3 (FAB100G). Cells were gated on Mouse Anti-Human Alexa Fluor® 405-conjugated CD14 (FAB3832V), Mouse Anti-Human PE-conjugated CD19 (FAB4867P), and Mouse Anti-Human Alexa Fluor® 700-conjugated CD56 (FAB24086N) negative populations. Staining was performed using our Staining Membrane-associated Proteins protocol. " > MAB1050), followed by Allophycocyanin-conjugated Anti-Rabbit IgG Secondary Antibody (F0111) and Mouse Anti-Human Alexa Fluor® 488-conjugated CD3 (FAB100G). Cells were gated on Mouse Anti-Human Alexa Fluor® 405-conjugated CD14 (FAB3832V), Mouse Anti-Human PE-conjugated CD19 (FAB4867P), and Mouse Anti-Human Alexa Fluor® 700-conjugated CD56 (FAB24086N) negative populations. Staining was performed using our Staining Membrane-associated Proteins protocol. " title="Human PBMC lymphocytes were stained with (A) Rabbit Anti-Human HVEM/TNFRSF14 Monoclonal Antibody (Catalog # MAB3563) or (B) isotype control antibody (MAB1050), followed by Allophycocyanin-conjugated Anti-Rabbit IgG Secondary Antibody (F0111) and Mouse Anti-Human Alexa Fluor® 488-conjugated CD3 (FAB100G). Cells were gated on Mouse Anti-Human Alexa Fluor® 405-conjugated CD14 (FAB3832V), Mouse Anti-Human PE-conjugated CD19 (FAB4867P), and Mouse Anti-Human Alexa Fluor® 700-conjugated CD56 (FAB24086N) negative populations. Staining was performed using our Staining Membrane-associated Proteins protocol. " />

Human PBMC lymphocytes were stained with (A) Rabbit Anti-Human HVEM/TNFRSF14 Monoclonal Antibody (Catalog # MAB3563) or (B) isotype control antibody (<a class=

MAB1050), followed by Allophycocyanin-conjugated Anti-Rabbit IgG Secondary Antibody (F0111) and Mouse Anti-Human Alexa Fluor® 700-conjugated CD56 (FAB24086N). Cells were gated on Mouse Anti-Human Alexa Fluor® 405-conjugated CD14 (FAB3832V), Mouse Anti-Human PE-conjugated CD19 (FAB4867P), and Mouse Anti-Human Alexa Fluor® 488-conjugated CD3 (FAB100G) negative populations. Staining was performed using our Staining Membrane-associated Proteins protocol. " > MAB1050), followed by Allophycocyanin-conjugated Anti-Rabbit IgG Secondary Antibody (F0111) and Mouse Anti-Human Alexa Fluor® 700-conjugated CD56 (FAB24086N). Cells were gated on Mouse Anti-Human Alexa Fluor® 405-conjugated CD14 (FAB3832V), Mouse Anti-Human PE-conjugated CD19 (FAB4867P), and Mouse Anti-Human Alexa Fluor® 488-conjugated CD3 (FAB100G) negative populations. Staining was performed using our Staining Membrane-associated Proteins protocol. " title="Human PBMC lymphocytes were stained with (A) Rabbit Anti-Human HVEM/TNFRSF14 Monoclonal Antibody (Catalog # MAB3563) or (B) isotype control antibody (MAB1050), followed by Allophycocyanin-conjugated Anti-Rabbit IgG Secondary Antibody (F0111) and Mouse Anti-Human Alexa Fluor® 700-conjugated CD56 (FAB24086N). Cells were gated on Mouse Anti-Human Alexa Fluor® 405-conjugated CD14 (FAB3832V), Mouse Anti-Human PE-conjugated CD19 (FAB4867P), and Mouse Anti-Human Alexa Fluor® 488-conjugated CD3 (FAB100G) negative populations. Staining was performed using our Staining Membrane-associated Proteins protocol. " />

Human PBMC lymphocytes were stained with (A) Rabbit Anti-Human HVEM/TNFRSF14 Monoclonal Antibody (Catalog # MAB3563) or (B) isotype control antibody (<a class=

MAB1050), followed by Allophycocyanin-conjugated Anti-Rabbit IgG Secondary Antibody (F0111) and Mouse Anti-Human Alexa Fluor® 405-conjugated CD14 (FAB3832V). Cells were gated on Mouse Anti-Human Alexa Fluor® 488-conjugated CD3 (FAB100G), Mouse Anti-Human PE-conjugated CD19 (FAB4867P), and Mouse Anti-Human Alexa Fluor® 700-conjugated CD56 (FAB24086N) negative populations. Staining was performed using our Staining Membrane-associated Proteins protocol. " > MAB1050), followed by Allophycocyanin-conjugated Anti-Rabbit IgG Secondary Antibody (F0111) and Mouse Anti-Human Alexa Fluor® 405-conjugated CD14 (FAB3832V). Cells were gated on Mouse Anti-Human Alexa Fluor® 488-conjugated CD3 (FAB100G), Mouse Anti-Human PE-conjugated CD19 (FAB4867P), and Mouse Anti-Human Alexa Fluor® 700-conjugated CD56 (FAB24086N) negative populations. Staining was performed using our Staining Membrane-associated Proteins protocol. " title="Human PBMC monocytes were stained with (A) Rabbit Anti-Human HVEM/TNFRSF14 Monoclonal Antibody (Catalog # MAB3563) or (B) isotype control antibody (MAB1050), followed by Allophycocyanin-conjugated Anti-Rabbit IgG Secondary Antibody (F0111) and Mouse Anti-Human Alexa Fluor® 405-conjugated CD14 (FAB3832V). Cells were gated on Mouse Anti-Human Alexa Fluor® 488-conjugated CD3 (FAB100G), Mouse Anti-Human PE-conjugated CD19 (FAB4867P), and Mouse Anti-Human Alexa Fluor® 700-conjugated CD56 (FAB24086N) negative populations. Staining was performed using our Staining Membrane-associated Proteins protocol. " />

Human PBMC monocytes were stained with (A) Rabbit Anti-Human HVEM/TNFRSF14 Monoclonal Antibody (Catalog # MAB3563) or (B) isotype control antibody (<a class=

• Reactivity: Hu
• Applications: Flow, B/N
• Clone: 2742B
• Clonality: Monoclonal
• Host: Rabbit
• Conjugate: Unconjugated

HVEM/TNFRSF14 Antibody (2742B) [Unconjugated] Summary

• Additional Information: Recombinant Monoclonal Antibody.
• Immunogen: Human embryonic kidney cell HEK293-derived human HVEM/TNFRSF14
  Pro37-Val202
  Accession # Q92956
• Specificity: Detects human HVEM/TNFRSF14 in ELISA.
• Source: N/A
• Isotype: IgG
• Clonality: Monoclonal
• Host: Rabbit
• Purity Statement: Protein A or G purified from cell culture supernatant

Applications/Dilutions

• Dilutions:
  • Flow Cytometry 0.25 ug/10^6 cells
  • Neutralization

Packaging, Storage & Formulations

• Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 6 months, -20 to -70 °C under sterile conditions after reconstitution.
• Buffer: Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose. *Small pack size (SP) is supplied either lyophilized or as a 0.2 µm filtered solution in PBS.
• Reconstitution Instructions: Reconstitute at 0.5 mg/mL in sterile PBS.

Notes

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Alternate Names for HVEM/TNFRSF14 Antibody (2742B) [Unconjugated]

• ATAR
• CD270 antigen
• CD270
• CD40-like protein
• Herpes virus entry mediator A
• Herpesvirus entry mediator A
• HveA
• HVEM
• HVEMTR2HVEAATAR
• LIGHTR
• TNFRSF14
• tumor necrosis factor receptor superfamily member 14
• tumor necrosis factor receptor superfamily, member 14 (herpesvirus entrymediator)
• Tumor necrosis factor receptor-like 2
• tumor necrosis factor receptor-like gene2

Background

HVEM (herpesvirus entry mediator), also known as TNFRSF14 and CD270, is a type I membrane protein in the TNF receptor superfamily, and it can both promote and inhibit T cell activity (1). Mature human HVEM consists of a 164 amino acid (aa) extracellular domain (ECD) with three cysteine-rich domains (CRD), a 21 aa transmembrane segment, and a 60 aa cytoplasmic tail with a TRAF interaction domain (2, 3). Within the ECD, human HVEM shares 55% aa sequence identity with mouse and rat HVEM. Alternative splicing generates an additional isoform with a substitution of the N-terminal 10 amino acids including the signal peptide. HVEM is highly expressed on naïve CD4⁺ T cells, CD8⁺ T memory cells, regulatory T cells, dendritic cells, monocytes, and neutrophils (4-8). Its expression declines during effector T cell activation but is up-regulated during Treg activation (4, 5). HVEM functions as a receptor for BTLA, CD160, LIGHT/TNFSF14, and Lymphotoxin-alpha (4, 9‑12). Ligation of HVEM by LIGHT triggers T cell, monocyte, and neutrophil activation (8, 10) and contributes to Th1 inflammation and cardiac allograft rejection (13, 14). In contrast, HVEM binding to CD160 or BTLA suppresses T cell and dendritic cell activation (4, 7, 9, 10) and dampens intestinal inflammation (15). HVEM enhances the development of CD8⁺ T cell memory and Treg function (5, 6). It is additionally expressed on intestinal epithelial cells, where its binding by intraepithelial lymphocyte (IEL) expressed CD160 promotes epitheilal integrity and host defense (16). The herpesvirus envelope glycoprotein gD, which binds HVEM to initiate membrane fusion, can antagonize both BTLA and LIGHT binding (2, 9, 11).

1. del Rio, M.L. et al. (2010) J. Leukoc. Biol. 87:223.
2. Montgomery, R.I. et al. (1996) Cell 87:427.
3. Hsu, H. et al. (1997) J. Biol. Chem. 272:13471.
4. Sedy, J. R. et al. (2005) Nat. Immunol. 6:90.
5. Tao, R. et al. (2008) J. Immunol. 180:6649.
6. Steinberg, M.W. et al. (2013) PLoS One 8:e77992.
7. de Trez, C. et al. (2008) J. Immunol. 180:238.
8. Heo, S.K. et al. (2006) J. Leukoc. Biol. 79:330.
9. Gonzalez, L.C. et al. (2005) Proc. Natl. Acad Sci. USA 102:1116.
10. Cai, G. et al. (2008) Nat. Immunol. 9:176.
11. Mauri, D.N. et al. (1998) Immunity 8:21.
12. Harrop, J.A. et al. (1998) J. Biol. Chem. 273:27548.
13. Wang, J. et al. (2005) J. Immunol. 174:8173.
14. Ye, Q. et al. (2002) J. Exp. Med. 195:795.
15. Steinberg, M.W. et al. (2008) J. Exp. Med. 205:1463.
16. Shui, J.W. et al. (2012) Nature 488:222.

Limitations

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

Bioinformatics

• Uniprot:
  • Q92956()